Tech Center 1600 • Art Units: 1621
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17798778 | DIRECT DELIVERY OF ANTIOXIDANTS TO THE GUT | Non-Final OA | DSM IP Assets B.V. |
| 18185225 | TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA WITH MIRDAMETINIB | Final Rejection | SpringWorks Therapeutics Inc. |
| 18113887 | THERAPEUTIC DRUG FOR MOTOR COMPLICATIONS IN PARKINSON'S DISEASE | Non-Final OA | SUMITOMO PHARMA CO., LTD. |
| 18323674 | LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR | Non-Final OA | Eli Lilly and Company |
| 17595581 | DIETARY BUTYRATE | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 17416577 | DIETARY BUTYRATE FOR TREATING OR PREVENTING AN ALLERGIC DISORDER | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 16276004 | Suppression and Inhibition of CDC25B with Safranal-Based Formulations | Final Rejection | United Arab Emirates University |
| 18115895 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | Non-Final OA | Gilead Sciences, Inc. |
| 18283855 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | Non-Final OA | CHIESI FARMACEUTICI S.P.A. |
| 18574513 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | Non-Final OA | QUÍMICA SINTÉTICA, S.A. |
| 18021238 | SOLID STATE FORMS OF ERDAFITINIB SALTS AND PROCESSES FOR PREPARATION OF ERDAFITINIB | Non-Final OA | ASSIA CHEMICAL INDUSTRIES LTD. |
| 18001420 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FGFR3-RELATED COGNITIVE DEFICIT | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) |
| 17620303 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | Non-Final OA | SAGE THERAPEUTICS, INC. |
| 18274441 | COMBINATION THERAPIES | Non-Final OA | MIRATI THERAPEUTICS, INC. |
| 18012278 | A COMBINATION OF A CBP/P300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC | Non-Final OA | TOLREMO THERAPEUTICS AG |
| 18282147 | ESTROGEN RECEPTOR ANTAGONIST | Non-Final OA | Shenzhen Forward Pharmaceuticals Co., Limited |
| 18547893 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | Non-Final OA | TYRA BIOSCIENCES, INC. |
| 17970448 | Magnetic-Responsive Photosensitizer Nanoplatform and Uses Thereof | Non-Final OA | University of Maryland, Baltimore |
| 18270450 | MODULATORS OF PROGRAMMED DEATH-LIGAND-1 | Non-Final OA | SOUTHERN RESEARCH INSTITUTE |
| 17802863 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Final Rejection | REMIX THERAPEUTICS INC. |
| 17775800 | METHODS OF TREATING LSD1-RELATED DISEASES AND DISORDERS WITH LSD1 INHIBITORS | Non-Final OA | Astex Pharmaceuticals, Inc. |
| 18173979 | DIHYDROQUINAZOLINONES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | Non-Final OA | VIB vzw |
| 17924101 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | Final Rejection | DURECT CORPORATION |
| 17971542 | TRIBUTYRIN SUPPLEMENTATION PROVIDES BENEFITS FOR MENTAL WELLNESS, IMMUNE HEALTH AND FAT METABOLISM | Final Rejection | PHARMAVITE LLC |
| 17863472 | TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS | Non-Final OA | GALMED RESEARCH AND DEVELOPMENT LTD |
| 17785939 | SIGMA-1 RECEPTOR LIGANDS AND USES THEREOF | Final Rejection | ECOLE PRATIQUE DES HAUTES ETUDES |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy